Background. More than one-third of American adults are obese, and an elevated body mass index (BMI) is postulated to reduce the sensitivity of the clinical evaluation of the axilla. Clinical nodal examination is important in allocating breast cancer patients to appropriate axillary management. This study sought to determine whether BMI influences the rate of nodal positivity in women designated clinically as node-negative (cN0) by physical examination. Methods. Breast cancer patients deemed cN0 who underwent sentinel lymph node biopsy (SLNB) from February 2006 to December 2011 were identified from a prospectively maintained database. Clinicopathologic features including BMI and axillary surgery results were recorded and compared among pathologically node-negative and node-positive patients. Results. Overall, 5142 cN0 patients underwent 5262 SLNB procedures during the study period. Nearly one-third of the patients (28 %) were obese (BMI, [30 kg/m 2 ). A positive SLN was identified in 25 % of the patients, and 84 % proceeded to axillary lymph node dissection. Predictors of SLN positivity included younger age, larger tumor size, high nuclear grade, multifocality, and lymphovascular invasion. An increased BMI did not correlate with a higher likelihood of SLN positivity (p = 0.6). The likelihood of cN0 patients having a high burden of axillary metastases ([3 positive nodes) was 4 % overall and, similarly, did not differ according to BMI (p = 0.4). Conclusion. Elevated BMI was not associated with a higher likelihood of SLN positivity or heavy nodal disease burden among women staged as cN0 by physical exam. These findings indicate that physical examination is appropriate and sufficient for preoperative axillary evaluation of women undergoing initial surgery regardless of patient BMI.
The prognostic significance of axillary lymph node metastases in patients with breast cancer has been recognized since the 1970s. 1 However, the surgical management of the axilla has changed substantially since that time. Evaluation of the axilla with sentinel lymph node biopsy (SLNB) has expanded considerably, with SLNB alone currently the standard staging procedure among all clinically node-negative (cN0) breast cancer patients. 2, 3 In addition, SLNB is increasingly the sole axillary surgical procedure among select patients with low-volume axillary metastases. [4] [5] [6] [7] The stratification of a breast cancer patient as clinically node positive or node negative is an important factor when treatment options are being considered. 8 Patients with palpable adenopathy at presentation are at risk for harboring heavier nodal disease burden, have confirmation of nodal metastasis by needle biopsy, and are managed with either upfront axillary lymph node dissection (ALND) or, increasingly, neoadjuvant chemotherapy. 9 In contrast, cN0 patients comprised the study populations that established the safety of SLNB alone for micro-and macro-metastatic axillary disease, 2, 5, [9] [10] [11] and frequently are spared the morbidity of ALND. 12 Therefore, the accuracy of the surgeons' nodal exam at presentation is paramount in allocating patients to the appropriate axillary treatment.
Little is known about the accuracy of the axillary clinical exam with varying patient body mass indices (BMI). This is a relevant topic to address because more than onethird of adults in the United States are obese, defined as a BMI greater than 30 kg/m 2 . 13 An elevated BMI is thought to reduce the sensitivity for certain clinical examinations, 14 and increasing BMI has been identified as a risk factor for failure of sentinel node mapping, 15, 16 but differences in the accuracy of the axillary physical exam based on patient BMI are unknown. It might be postulated that physical examination is less sensitive for obese patients who would therefore be at higher risk for having axillary nodal metastasis on SLNB, even with a benign axillary exam. This study sought to compare the likelihood of SLN metastasis among obese and non-obese cN0 breast cancer patients to determine whether the ability to clinically identify nodal positivity and heavy nodal disease burden differs by patient BMI.
METHODS
After Memorial Sloan Kettering Cancer Center (MSKCC) institutional review board approval was received, consecutive patients who underwent SLNB from 1 February 2006 to 30 December 2011 were identified from a prospective institutional database. Patients eligible for inclusion in the study were those with biopsy-proven invasive breast cancer who were deemed cN0 on the basis of preoperative physical examination. Patients undergoing neoadjuvant chemotherapy and patients with palpable adenopathy were excluded from the study. Although some patients had axillary ultrasound performed before presentation at MSKCC, axillary ultrasound was not a routine part of the diagnostic workup for cN0 patients with de novo breast cancer.
A random sample comprising 10 % of the patient population (n = 530) was reviewed to assess axillary ultrasound use. Overall, 25 % of the women underwent axillary ultrasound, 67 % of which were performed at an outside institution before presentation at MSKCC. Ultrasound use by patient BMI did not vary significantly.
Patient characteristics, including height and weight at the time of surgical treatment, were available for all identified cases. Details of breast and axillary surgery (failure of SLNB, SLNB alone, SLNB, and ALND) were obtained from procedure reports. Pathology records were reviewed, and total number of SLNs removed, number of positive SLNs, ALND total and positive lymph node yield, and final N stage were identified. Lymph nodes were designated as positive for the presence of either micro-or macro-metastases. Isolated tumor cells were classified as node negative. Completion ALND during this period was routinely performed for all pathologically node-positive (pN?) patients. After publication of the American College of Surgical Oncology Group (ACOSOG) Z0011 study in 2010, 5 patients who met the Z0011 eligibility criteria underwent completion ALND for three or more positive SLNs or gross extracapsular extension. The SLNB procedure was performed using dual-modality mapping with technetium-99m and isosulfan blue dye or with the use of isosulfan blue dye alone, based on the surgeon's preference.
In this study, BMI was assessed both as a continuous variable and as a categorical variable based on the World Health Organization classification of BMI, 17 which defined BMI less than 18.5 kg/m 2 as underweight, 18.5-24.9 kg/ m 2 as normal weight, 25.0-29.9 kg/m 2 as overweight/preobese, and 30 kg/m 2 or more as obese. Statistical analysis was performed using R 3.1.1 (R Foundation, Vienna, Austria). Associations between outcomes of interest and categorical variables were assessed using the v 2 test, and associations between outcomes of interest and continuous variables were assessed using Wilcoxon rank-sum test. A p value lower than 0.05 was considered statistically significant. Table 1 outlines the clinicopathologic features for the entire cohort and by pathologic nodal status.
RESULTS

Between
The sentinel lymph node (SLN) contained metastases in 25 % of the cases (n = 1314), with 6 % (n = 318) of the population found to have micrometastases and 19 % (n = 996) found to have macrometastases. Among the 1314 patients with a positive SLN, 76 % (n = 996) had one or two positive nodes, 8 % (n = 102) had three positive nodes, and 16 % (n = 216) had four or more positive nodes. Only 318 patients (6.2 %) in the overall cohort had more than two positive lymph nodes.
An increased BMI did not correlate with a higher likelihood of SLN positivity, whether evaluated as a continuous (p = 0.31) or categorical (p = 0.58) variable. The rate of macrometastatic nodal disease alone (CpN1) did not vary according to patient BMI (p = 0.5; Table 2 ) and, similarly, the likelihood of cN0 patients having a high burden of axillary metastases (CpN2 disease) did not differ according to BMI (p = 0.47) (Fig. 2) . Known clinicopathologic factors predicted nodal positivity, including younger age, larger primary tumor size, high nuclear grade, and tumor multifocality as well as the presence of lymphovascular invasion (p \ 0.001; Table 1 ).
The average number of SLNs removed was two for the entire cohort (Table 2 ). Among the pN? patients, 994 (76 %) underwent a completion ALND. An additional 224 pN? patients who had undergone breast-conserving surgery and met the Z0011 criteria underwent SLNB alone for axillary metastases in two or fewer SLNs.
An SLN was identified in 99.1 % of the cases. Whereas the rate of failed SLN mapping was higher in obese versus non-obese patients (1.6 vs. 0.5 %; p = 0.003), among the obese cohort, an SLN was identified in more than 98 % of the cases (Table 3) . Among the patients with class 1 obesity (BMI 30-35 kg/m 2 ), the rate of failure to identify SLN was 1.1 %, rising to 1.7 % among the patients with class 2 obesity (BMI 35-40 kg/m 2 ) and 3.3 % among the patients with class 3 obesity (BMI C40 kg/m 2 ) (p \ 0.001). Overweight and obese patients were more likely to have been treated with breast-conserving surgery than those with a BMI lower than 25 kg/m 2 . In addition, the overweight and obese patients were significantly older than the non-obese patients (respectively, 61 and 62 vs. 51 years; p [ 0.001).
DISCUSSION
Evidence from randomized clinical trials during the last two decades has heralded practice-changing advances in the surgical management of the axilla in breast cancer patients. 18 In this study, we demonstrated, in a cohort of more than 5200 patients, that rates of SLN positivity did not differ among cN0 women with varying BMI classifications, suggesting similar accuracy of the axillary physical exam for obese and non-obese patients.
Despite advances in estimation of prognosis and prediction of response to adjuvant therapy, axillary lymph node status remains a critical component in surgical decision making and in determining therapeutic strategies. The finding of palpable adenopathy, when corroborated by a positive axillary ultrasound and needle biopsy, is used to allocate patients to either neoadjuvant chemotherapy or upfront ALND. In comparison, SLNB is the standard for axillary staging among cN0 patients. The success of SLNB is predicated on the basis of a high technical success rate, low false-negative rate, and less postoperative morbidity than with ALND. 7, 19 Landmark trials such as ACOSOG Z0011 5 and After Mapping of the Axilla: Radiotherapy Or Surgery? (AMAROS) 10 that included patients with macro-metastatic nodal disease identified patients with positive SLNs for whom further axillary surgery can be omitted without compromise of regional or overall disease-free survival. Our findings demonstrated that only 6 % of cN0 patients will have a final pathologic nodal yield of more than two positive nodes and that this risk of clinically occult heavy nodal burden is not increased in patients with an elevated BMI. These findings support the value of SLNB without additional preoperative axillary imaging for axillary staging among all cN0 patients, regardless of body habitus. The technical success of SLNB mapping did differ among women in different BMI categories, even among a group of experienced breast specialists. Obese patients had a higher rate of failed SLNB mapping, with failure rates ranging from 0.5 % in normal/underweight patients to 3.3 % in class 3 obese patients. Previous studies have implicated both obesity and increased age as patient factors that reduce the success of SLNB. 15, 16, 20 However, the absolute difference of less than 3 % in SLN identification among the extremes of BMI classifications is likely not clinically meaningful, considering that among all obese patients, more than 98 % had successful SLN mapping.
In addition to physical examination, some advocate the use of axillary ultrasound to identify patients with nodal metastases preoperatively to obviate the need for SLNB. A meta-analysis has shown that preoperative staging axillary ultrasound coupled with fine-needle aspiration or core biopsy of suspicious or abnormal nodes will correctly identify approximately 50 % of node-positive patients. 21 However, the role of axillary imaging in cN0 patients meeting the ACOSOG Z0011 criteria has been questioned. We have previously demonstrated that identification of abnormal nodes on preoperative imaging 22 or even a positive needle biopsy 23 does not reliably identify a group of patients who require ALND when ACOSOG Z0011 eligibility criteria are otherwise met. Although studies have not shown BMI to have an impact on the sensitivity of axillary ultrasound, [24] [25] [26] our data suggest that obesity itself is not an indication for additional axillary evaluation.
This was a retrospective review with the associated limitations. Although the majority of the patients at our institution are designated as cN0 by physical exam alone, approximately one-fourth of the women in this study cohort underwent axillary ultrasound. The SLN positivity rate of 25 % seen in this study is similar to the 29 % seen in National Surgical Adjuvant Breast and Bowel Project (NSABP) B32 2 and the 25 % seen in the Axillary Lymphatic Mapping Against Nodal Axillary Clearance (ALMANAC) trial, 16 two multicenter trials that randomized cN0 patients without the use of axillary ultrasound. Therefore it is unlikely that a large cohort of patients exist that were deemed cN0 by physical exam, but who, on the basis of positive findings via axillary ultrasound, were excluded from upfront SLNB. Furthermore, it is our practice to stage clinically node-negative patients with an SLNB who meet the ACOSOG Z0011 criteria regardless of axillary ultrasound findings.
The strengths of this study included a large patient cohort with available patient and pathologic data. Our results replicate a number of known risk factors for nodal metastases among cN0 patients, including age, tumor size, grade, lymphovascular invasion, and multifocality, but these, importantly, do not show a difference in overall node positivity or heavy nodal disease burden based on patient BMI.
Elevated BMI is not associated with a higher likelihood of SLN positivity or heavy nodal disease burden among women staged as cN0 by physical exam. Clinical assessment of axillary status of newly diagnosed breast cancer in patients with physical examination appears equivalent in non-obese and obese patients, and remains an appropriate evaluation for axillary treatment allocation regardless of patient BMI.
